Living with psoriatic arthritis (PsA) involves managing a unique and often frustrating combination of symptoms. Patients frequently navigate morning stiffness that makes getting out of bed a challenge, alongside the skin irritation of psoriasis. The condition can affect large joints like the knees or smaller ones in the fingers and toes, sometimes causing “sausage-like” swelling known as dactylitis. Fatigue is another common companion, making even simple daily tasks feel exhausting. While the unpredictable nature of flare-ups can be stressful, effective management is available to help regain control.

Treatment is critical not only for relieving pain but for preventing permanent joint damage. Unchecked inflammation can erode bone and cartilage over time, leading to loss of function. Because PsA varies widely, ranging from mild joint nagging to severe, erosive disease, treatment plans are highly personalized. Doctors tailor medication choices based on which joints are affected, the severity of skin symptoms, and the patient’s overall medical history (National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2023).

Overview of treatment options for Psoriatic Arthritis

The primary goal of treatment is to achieve remission or low disease activity. This means reducing inflammation to a point where symptoms are minimal and joint damage stops. The approach typically follows a “step-up” strategy: starting with milder medications for mild symptoms and moving to more potent therapies if the disease is active or severe.

Pharmacological treatment focuses on calming the overactive immune system. While physical therapy and lifestyle changes support joint health, medications are the only tool capable of halting the biological progression of the disease. Treatment usually involves long-term maintenance rather than short-term fixes, requiring regular follow-ups to adjust therapy as needed.

Medications used for Psoriatic Arthritis

For mild cases involving joint pain without significant damage, nonsteroidal anti-inflammatory drugs (NSAIDs) are often the first line of defense. Common over-the-counter options include ibuprofen and naproxen, while prescription strengths are available for more stubborn pain. These help reduce swelling and discomfort but do not alter the course of the disease.

When symptoms are moderate to severe, or if joint damage is a risk, doctors prescribe disease-modifying antirheumatic drugs (DMARDs). Traditional oral DMARDs, such as methotrexate, sulfasalazine, and leflunomide, are standard choices. These are often effective for peripheral joint issues and skin symptoms.

If traditional DMARDs are ineffective, or if the disease affects the spine (axial disease), Biologic DMARDs are introduced. This powerful class includes Tumor Necrosis Factor (TNF) inhibitors like adalimumab and etanercept. Newer biologics target other specific immune pathways, such as Interleukin-17 (IL-17) inhibitors (e.g., secukinumab) or IL-23 inhibitors.

For patients who prefer oral pills over injections, or for those who do not respond to biologics, JAK inhibitors like tofacitinib or upadacitinib are potent options. Corticosteroids may be injected directly into a painful joint for temporary relief during a flare (Arthritis Foundation, n.d.; cited via MedlinePlus, 2022).

How these medications work

NSAIDs block prostaglandin-producing enzymes, treating pain and swelling (symptoms) without addressing the underlying immune cause.

DMARDs and biologics modify the immune system. Traditional DMARDs broadly suppress the immune response to reduce inflammation. Biologics are targeted; they block specific inflammation-fueling proteins (cytokines). For example, TNF inhibitors block tumor necrosis factor, stopping the signal for the body to attack its joints.

JAK inhibitors work inside the cell. They block the “Janus kinase” pathways, which are signaling routes the cells use to trigger inflammation. By closing off this route, the inflammatory cycle is interrupted from within (Food and Drug Administration, 2021).

Side effects and safety considerations

PsA medications, often immunosuppressants, increase infection risk. Biologics and JAK inhibitors require tuberculosis and hepatitis screening beforehand. Common side effects include injection site reactions for biologics, and nausea/liver strain for methotrexate.

Long-term NSAID use necessitates monitoring for stomach, kidney, and heart issues. Patients on DMARDs require regular blood tests (liver enzymes, blood cell counts). Live vaccines should generally be avoided while on immunosuppressive drugs. Seek immediate medical attention for high fever, severe infection signs, or breathing difficulty. Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. https://www.niams.nih.gov
  2. MedlinePlus. https://medlineplus.gov
  3. Food and Drug Administration. https://www.fda.gov
  4. Mayo Clinic. https://www.mayoclinic.org

Medications for Psoriatic Arthritis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Psoriatic Arthritis.

Found 25 Approved Drugs for Psoriatic Arthritis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Adalimumab

Brand Names
Adalimumab-aacf, Humira

Adalimumab

Brand Names
Adalimumab-aacf, Humira
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.

Enbrel

Generic Name
Etanercept

Enbrel

Generic Name
Etanercept
Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA).

Cosentyx

Generic Name
Secukinumab

Cosentyx

Generic Name
Secukinumab
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

Adalimumab-ADAZ

Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima

Adalimumab-ADAZ

Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima
Plaque Psoriasis HYRIMOZ is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HYRIMOZ should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Ulcerative Colitis HYRIMOZ is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF-blockers [see Clinical Studies (1. HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: Rheumatoid Arthritis (RA).
Showing 1-5 of 25
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances